GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » ROE %

Aravive (Aravive) ROE % : Negative Equity% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Aravive ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Aravive's annualized net income for the quarter that ended in Sep. 2023 was $84.90 Mil. Aravive's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $-9.06 Mil. Therefore, Aravive's annualized ROE % for the quarter that ended in Sep. 2023 was Negative Equity%.

The historical rank and industry rank for Aravive's ROE % or its related term are showing as below:

ARAV's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.1
* Ranked among companies with meaningful ROE % only.

Aravive ROE % Historical Data

The historical data trend for Aravive's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive ROE % Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -106.98 -28.25 -52.16 -86.74 -288.67

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -277.79 -906.65 - Negative Equity Negative Equity

Competitive Comparison of Aravive's ROE %

For the Biotechnology subindustry, Aravive's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's ROE % distribution charts can be found below:

* The bar in red indicates where Aravive's ROE % falls into.



Aravive ROE % Calculation

Aravive's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-76.322/( (42.222+10.657)/ 2 )
=-76.322/26.4395
=-288.67 %

Aravive's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=84.904/( (-19.817+1.701)/ 2 )
=84.904/-9.058
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Aravive  (NAS:ARAV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=84.904/-9.058
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(84.904 / 11.024)*(11.024 / 19.393)*(19.393 / -9.058)
=Net Margin %*Asset Turnover*Equity Multiplier
=770.17 %*0.5685*N/A
=ROA %*Equity Multiplier
=437.84 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=84.904/-9.058
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (84.904 / 84.904) * (84.904 / -35.656) * (-35.656 / 11.024) * (11.024 / 19.393) * (19.393 / -9.058)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * -2.3812 * -323.44 % * 0.5685 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Aravive ROE % Related Terms

Thank you for viewing the detailed overview of Aravive's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (Aravive) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Executives
Maria Carolina Petrini officer: Chief Commercial Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard officer: Chief Financial Officer 322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove officer: Chief Operating Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia director, 10 percent owner C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre officer: Chief Scientific Officer C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk director 225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc director 319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani director, officer: President and CEO 3928 POINT EDEN WAY, HAYWARD CA 94545

Aravive (Aravive) Headlines

From GuruFocus

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

By GuruFocusNews GuruFocusNews 07-05-2022

Aravive to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 07-06-2022